On 26th September 2017, Arnie Clarke was representing one of two opponents to successfully seek revocation of EP2036557 at the European Patent Office (EPO).
The EPO revoked the patent on the basis that the claims lacked an inventive step.
The parent concerned Lenvima, known chemically as lenvatinib, for the treatment of thyroid carcinoma. Lenvima has been authorised for sale in a number of European countries and in the USA.
Lenvatinib is an oral kinase inhibitor that targets a number of cellular factors that can encourage tumour growth, including vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) and platelet-derived growth factor receptors (PDGF), as well as RET and KIT.
Eisai is testing it against other cancers and expects the drug to hit $1 billion in annual sales by 2020.
If you would like more information, please contact a member of GJE’s oppositions team who will be happy to assist.